Clinical Trial Detail

NCT ID NCT02091999
Title A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

lung non-small cell carcinoma

peritoneal carcinoma

urethra transitional cell carcinoma

fallopian tube cancer

ovary epithelial cancer

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Enfortumab vedotin-ejfv

Age Groups: adult senior

No variant requirements are available.